Literature DB >> 11043422

A transforming growth factor-beta1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura.

P O Andersson1, D Stockelberg, S Jacobsson, H Wadenvik.   

Abstract

Bystander immune suppression has been demonstrated in experimental models of oral immune tolerance induction. This phenomenon is associated with expression of transforming growth factor (TGF)-beta1 and T-helper cell (Th) 2 cytokines. We have studied serum levels of Th cytokines and B- and T-lymphocyte subsets in chronic idiopathic thrombocytopenic purpura (ITP), a disorder in which the production of platelet autoantibodies might be caused by a cytokine network dysregulation. Forty-six patients with ITP were separated into three groups depending on the platelet count (pltc): (1) < 50 x 10(9)/l, (2) 50-150 x 10(9)/l and (3) > 150 x 10(9)/l. We found significantly elevated plasma levels of the Th3 cytokine TGF-beta1 in patients with pltc >150x10(9)/l (23.5+/-2.8ng/ml), compared with patients with pltc <50x10(9)/l (2.3+/-0.6 ng/ml; P<0.0001), patients with pltc 50-150x 10(9)/l (7.2+/-1.7 ng/ml; P<0.0001) and healthy volunteers (9.8+/-1.3 ng/ml; P<0.01). The serum levels of the Thl cytokines interleukin (IL)-2 and interferon (IFN)-y were below the detection limits of the assays. Likewise, the Th2 cytokine IL-4 was not detectable or was very low both in patients and controls. The serum levels of IL-10, a Th2 cytokine, were within the assay range and patients with pltc <50 x 10(9)/l had significantly lower levels (0.6+/-0.1 pg/ml) than both patients with pltc 50-150 x 10(9)/l (1.8 +/- 0.1 pg/ml; P<0.005) and healthy volunteers (1.4+/-0.1 pg/ml; P<0.005). Furthermore, patients with pltc <50 x 10(9)/l and splenectomised patients had significantly higher levels of CD4 + CD25 + activated T cells [26.2 +/- 14.8% (P<0.05) and 26.7+/-11.9% (P<0.005), respectively] than healthy controls (16.5+/-4.0%). Also, the number of natural killer (NK) cells among patients with pltc >150 x 10(9)/l were significantly elevated (26.6+/-16.0%; P<0.05) compared with controls (17.4+/-7.6%). In conclusion, our data corroborate previous findings of elevated numbers of activated T cells in chronic ITP patients with active disease, but neither a clear-cut Th1 nor a Th2 serum cytokine profile could be established. However, ITP in remission was associated with elevated TGF-beta1, which might be a part of a bystander immune suppression. We propose that the effect of possible expression of TGF-beta1 by oral immune tolerance induction deserves to be explored in ITP patients with an active disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11043422     DOI: 10.1007/s002770000177

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  18 in total

Review 1.  Platelets in the pathogenesis of acute respiratory distress syndrome.

Authors:  Hemang Yadav; Daryl J Kor
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-08-28       Impact factor: 5.464

Review 2.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

3.  Inflammatory responses improve with milk ribonuclease-enriched lactoferrin supplementation in postmenopausal women.

Authors:  Satish Bharadwaj; Tezus A G Naidu; Guru V Betageri; Nemani V Prasadarao; A Satyanarayan Naidu
Journal:  Inflamm Res       Date:  2010-05-15       Impact factor: 4.575

Review 4.  Platelets and the immune continuum.

Authors:  John W Semple; Joseph E Italiano; John Freedman
Journal:  Nat Rev Immunol       Date:  2011-04       Impact factor: 53.106

5.  Platelet recovery in patients with idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori.

Authors:  S Hashino; A Mori; S Suzuki; K Izumiyama; K Kahata; M Yonezumi; K Chiba; T Kondo; S Ota; N Toyashima; N Kato; J Tanaka; M Imamura; M Asaka
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

6.  Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents.

Authors:  Weili Bao; James B Bussel; Susanne Heck; Wu He; Marissa Karpoff; Nayla Boulad; Karina Yazdanbakhsh
Journal:  Blood       Date:  2010-08-05       Impact factor: 22.113

Review 7.  The role of autoreactive T-cells in the pathogenesis of idiopathic thrombocytopenic purpura.

Authors:  Masataka Kuwana; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2005-02       Impact factor: 2.490

8.  Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells.

Authors:  Baijun Fang; Ling Mai; Ning Li; Yongping Song
Journal:  Stem Cells Dev       Date:  2011-08-12       Impact factor: 3.272

9.  Alterations in immune cell subsets and their cytokine secretion profile in childhood idiopathic thrombocytopenic purpura (ITP).

Authors:  R M Talaat; A M Elmaghraby; S S Barakat; M El-Shahat
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

10.  A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?

Authors:  Dana N LeVine; Adam J Birkenheuer; Marjory B Brooks; Shila K Nordone; Dwight A Bellinger; Sam L Jones; Thomas H Fischer; Stephen E Oglesbee; Kahlina Frey; Nicole S Brinson; Allison P Peters; Henry S Marr; Alison Motsinger-Reif; Sif Gudbrandsdottir; James B Bussel; Nigel S Key
Journal:  Br J Haematol       Date:  2014-07-08       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.